Contribution: Industrial Research Assistance Program – Contributions to Firms
Ripple Therapeutics Corp.
$50,000.00
Development of New Materials for the Treatment of Opioid use disorder
FY 2021-22 · 2021-11-16
Summary
The goal of this project is to engineer unique drug delivery systems using prodrug materials that will improve upon current controlled drug release technologies for the treatment of opioid use disorder. This will involve evaluating chemically modifying an API so that it can be processed into a sustained release injectable form that exhibits surface erosion based drug release without the use of polymers or excipients. This work will be pursued for APIs in the opioid antagonist drug class
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
760459073
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-11-16 | 2021-22 | $50,000.00 |
| 1 | 2021-11-16 | 2021-22 | $50,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 30 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 30 jours.
Agreement End Date
2022-11-30
Agreement Number
982618
Agreement Start Date
2021-11-16
Agreement Title
Development of New Materials for the Treatment of Opioid use disorder
Agreement Title (French)
Création de nouveaux matériaux pour le traitement du trouble de l'usage des opioïdes
Agreement Type
Contribution
Agreement Value
$50,000.00
Amendment Date
2022-10-19
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The goal of this project is to engineer unique drug delivery systems using prodrug materials that will improve upon current controlled drug release technologies for the treatment of opioid use disorder. This will involve evaluating chemically modifying an API so that it can be processed into a sustained release injectable form that exhibits surface erosion based drug release without the use of polymers or excipients. This work will be pursued for APIs in the opioid antagonist drug class
Description (French)
L'objectif de ce projet est de concevoir des systèmes uniques d'administration de médicaments en utilisant des prodrogues qui amélioreront les technologies actuelles de libération contrôlée de médicaments pour le traitement des troubles liés à la consommation d'opiacés. Il s'agira d'évaluer la modification chimique d'un IPA afin qu'il puisse être transformé en une forme injectable à libération prolongée. Cette forme présente une libération de médicament basée sur l'érosion de surface sans l'utilisation de polymères ou d'excipients. Ce travail sera poursuivi pour les IPA de la classe des antagonistes opioïdes.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
32541
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
760459073
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Ripple Therapeutics Corp.
Recipient Operating Name
Ripple Therapeutics
Recipient Postal Code
M5G 1L7
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2021-2022-Q3-982618
